Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing clinical outcome measures in multiple sclerosis: an evolving process

Alan J Thompson

    Multiple Sclerosis (Houndmills, Basingstoke, England)
    |October 3, 2002
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

    Health technology assessment (Winchester, England)·2026
    Same author

    Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply.

    The Lancet. Neurology·2026
    Same author

    Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury.

    Nature communications·2026
    Same author

    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.

    Neurology·2026
    Same author

    Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

    Lancet (London, England)·2025
    Same author

    Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.

    BMJ open·2025
    Same journal

    Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    Same journal

    Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    Same journal

    Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    Same journal

    Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    Same journal

    Racial identity, marginalization, and depression in pediatric-onset multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    Same journal

    Disability and race in MS: Does socioeconomic disadvantage play a role?

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026
    See all related articles